

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: August 18, 2010 (use as many sheets as necessary)		<b>Application Number</b>	10/588,028
		<b>Filing Date</b>	4/30/2007
		<b>First Named Inventor</b>	Himanshu BRAHMBHATT
		<b>Art Unit</b>	1632
		<b>Examiner Name</b>	Anoop Kumar SINGH
		<b>Attorney Docket Number</b>	060348-0149

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	†*
	E1	Letter from Knobbe Martens Olson & Bear LLP dated February 26, 2010.	
	E2	Manisha P. DESAI et al., "The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells is Size Dependent", <i>Pharmaceutical Research</i> , Vol. 14, No. 11, 1997, pp. 1568-1573.	
	E3	Igor DIMITRIEV et al., "Ectodomain of Coxsackievirus and Adenovirus Receptor Genetically Fused to Epidermal Growth Factor Mediates Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells", <i>Journal of Virology</i> , Aug. 2000, Vol. 74, No. 15, pp. 6875-6884.	
	E4	Christoph MAMOT et al., "Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRVIII-overexpressing Tumor Cells", <i>Cancer Research</i> , June 2003, Vol. 63, 3154-3161.	
	E5	William F. SCHERER M.D. et al., "THE VIRAL RANGE IN VITRO OF A MALIGNANT HUMAN EPITHELIAL CELL (STRAIN HELA, GEY) - III. Studies with Pseudolymphocytic Choriomeningitis Virus General Discussion", <i>American Journal of Pathology</i> , Jan-Feb 31(1): 31-39 (1954).	
	E6	Masahisa WATARAI et al., "Interaction of Ipa Proteins of <i>Shigella flexneri</i> with $\alpha_5\beta_1$ Integrin Promotes Entry of the Bacteria into Mammalian Cells", <i>J. Exp. Med.</i> Vol. 183, March 1996, pp. 991-999.	
	E7	Tibor PAL et al., "Plasmid-Associated Adherence of <i>Shigella flexneri</i> in a HeLa Cell Model", <i>INFECTION AND IMMUNITY</i> , Aug 1989, Vol. 57, No. 8, pp. 2580-2582.	
	E8	William F. SCHERER et al., "STUDIES OF THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES", <i>Journal of Experimental Medicine</i> , Vol. 97, No. 5, pp. 695-710 (1953).	
	E9	Aline JAFFE et al., "Minicell-Forming Mutants of <i>Escherichia coli</i> : Production of Minicells and Anucleate Rods", <i>Journal of Bacteriology</i> , Vol. 170, No. 7, July 1988, pp. 3094-3101.	
	E10	Thomas L. HALE et al., "Characterization of Virulence Plasmids and Plasmid-Associated Outer Membrane Proteins in <i>Shigella flexneri</i> , <i>Shigella sonnei</i> , and <i>Escherichia coli</i> ", <i>Infection and Immunity</i> , April 1983, Vol. 40, No. 1, pp. 340-350.	
	E11	Gary J. DOHERTY et al., "Mechanisms and Endocytosis", <i>Annu. Rev. Biochem.</i> March 14, 2009, 78:31.1-31.46.	
	E12	Pascal PESCHARD, "Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases", <i>CANCER CELL</i> , June 2003, Vol. 3, pp. 519-523.	
	E13	Emmanouil D. KARAGIANNIS et al., "Minicells overcome tumor drug-resistance", <i>NATURE BIOTECHNOLOGY</i> , Vol. 27, No. 7, July 2009, pp. 620-621.	

Examiner Signature	/Anoop Singh/	Date Considered	09/09/2011
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is a file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WASH\_7259803.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./